Could a bone marrow drug help Alzheimer's patients?

NCT ID NCT04902703

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether sargramostim, a drug already approved to stimulate bone marrow, is safe and effective for people with mild-to-moderate Alzheimer's disease. Over 6 months, 42 participants will receive either the drug or a placebo. The study will monitor side effects and measure changes in cognitive function using standard tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sargramostim (also known as Leukine or GM-CSF)
What this could lead to: If it works, this could point toward a new treatment that slows cognitive decline in Alzheimer's disease.
What could go wrong: This is a small, early-phase trial with only 42 participants, so results may not apply to everyone. The drug is being repurposed, and its effects on Alzheimer's are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

University of Colorado Anschutz Medical Campus
RECRUITING

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.